相关实验视频

Updated: Sep 13, 2025

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

在逆转胺治疗后循环ANGPTL3/8度的降低与血清脂质的并行降低相对应

Yi Wen¹, Deven Lemen¹, Yanzhu Lin¹

¹Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.

Diabetes, obesity & metabolism

|July 29, 2025

概括

雷塔鲁提德是一种三重激动剂,通过降低ANGPTL3/8水平来降低甘油三和LDL胆固醇. 这种效应与葡萄糖受体激动性有关,这表明一种新的脂质管理机制.

科学领域:

代谢性疾病是一种代谢性疾病.
药理学药理学是指药理学的学科.
脂质代谢脂质的代谢

背景情况:

高甘油 (TG) 和低密度脂蛋白胆固醇 (LDL-C) 是心血管疾病的关键风险因素.
血管蛋白样蛋白3/8 (ANGPTL3/8) 复合体是脂质代谢的调节者.
雷塔胺是一种新型的三重激动剂,向GIP,GLP-1和GCG受体.

研究的目的:

通过降低 ANGPTL3/8 度来研究雷达胺是否会降低血清TG和LDL-C.
探索ANGPTL3/8在雷达胺降脂效应中的作用.

主要方法:

两项二期复原二甲试验的后期分析.
使用免疫试验测量ANGPTL3/8,ANGPTL4/8,ANGPTL3和ANGPTL4的测量.
在人肝细胞中对ANGPTL3/8分泌的Retatrutide作用的体外研究.

主要成果:

在2型糖尿病的参与者和肥胖/超重的参与者中,雷他类治疗导致ANGPTL3/8水平显著降低.
降低ANGPTL3/8的同时降低了TG和LDL-C.
在实验室中,复原和葡萄糖降低了ANGPTL3/8的分泌,这种效应被GCGR抗体阻断.

结论:

雷塔丁的葡萄糖受体激动作用有助于降低ANGPTL3/8度.
这种降低ANGPTL3/8可能是雷达胺降低TG和LDL-C的关键机制.
这些研究结果表明,使用雷达化来管理脂质不良症是一种新的途径.

关键词:

血管蛋白类蛋白 (ANGPTL) 是一种类似于血管蛋白的蛋白质.葡萄糖 (GCG) 的使用低密度脂蛋白胆固醇 (LDL-C) 是一种逆转的时间逆转的时间三甘油 (TG) 的使用.

更多相关视频

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...